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Commentary 
Heparin: A drug of varying composition and effectiveness 
William W. Coon, M.D. Ann Arbor, Mich. 
The Department of Surgery, Section of General Surgery, University of 
Michigan Medical Center 
In the past few years concerns have been ex-
pressed by clinical investigators regarding the 
variable and unpredictable risk of both hemor-
rhage and thrombosis in patients receiving 
heparin. Recent observations tend to indicate 
that a number of elements may contribute to 
variability in response to heparin. Possible fac-
tors which may be responsible include differ-
ences in chemical composition and in methods 
of assay, variable absorption, different types 
and degrees of alteration in coagulation 
mechanism of patients, and inaccuracies or in-
adequacies in methods for monitoring therapy. 
Several commercial heparins have been 
shown to contain 21 components varying in 
molecular weight12 and in elemental composi-
tion, electrophoretic mobility, and nuclear mag-
netic spectrum. 8 When several assay methods 
are compared, a 12-fold difference in activity 
has been found between heparin of relatively 
low molecular weight and higher molecular 
weight material. 1 If preparations of commercial 
heparin are isolated on matrix-bound anti-
thrombin III, a large proportion of the material 
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has been shown to have low activity while the 
remaining "active" one third contains 85% of 
the anticoagulant effect. 7 
The problems of reproducibility of the in 
vitro coagulation tests used for assay of heparin 
as defined in the United States Pharmacopeia 
and British Pharmacopaeia have been known 
for many years, but no more satisfactory 
method has yet been developed. It is not surpris-
ing that in vitro clotting tests performed on ani-
mal plasma may not reflect the anti thrombotic 
effectiveness of heparin in vivo in human whole 
blood. While standardization of preparations of 
heparin in vivo in man or animals would be 
more expensive, it might also prove to be con-
siderably more reliable1o; a problem with utili-
zation of in vivo assay in animals is the differ-
ences in hemostatic mechanisms between spe-
cies. Ideally, if heparin standards ·were 
homogeneous and could be characterized by 
physical and chemical methods, a chemical 
procedure might be developed, but this would 
require the acquisition of considerably more in-
formation than is now available on the re-
lationship between physicochemical differences 
in heparin preparations and anti thrombotic ef-
fect. 
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Variations in assays of heparin activity have 
resulted when a preparation from one tissue or 
species is compared with a standard from an-
other tissue or species. 3 However, this finding 
together with the known heterogeneity of tissue 
heparins cannot be extrapolated to imply that 
currently available commercial heparins, when 
administered in a fixed dose in United States 
Pharmacopeia units, vary in anticoagulant 
activity with species or tissue source. In the 
past few years poorly documented claims that 
beef lung heparin is superior to porcine mucosal 
heparin have been published. These statements 
have not been substantiated when carefully 
controlled double-blind crossover trials measur-
ing in vivo anticoagulant effect have been con-
ducted.2. 11 
Differences in frequency of bleeding have 
been reported when several preparations of 
heparin are injected subcutaneously. Since the 
calcium salt of heparin was associated with a 
lower prevalence of hemorrhagic problems than 
the sodium salt, it was initially thought to be a 
preferable product. A recent study, however, 
has shown that subcutaneous injection of cal-
cium heparin results in lower blood levels of 
heparin than those achieved by injection of the 
same number of units of sodium heparin, indi-
cating that a lesser amount of the former is ab-
sorbed. 15 The molecular weight of heparin also 
influences degree of subcutaneous absorption. 9 
Although clinicians have recognized for some 
time that the anticoagulant response after subcu-
taneous injection may be highly variable, par-
ticularly with relatively small doses, these are 
the first good data to indicate that the structure 
of the heparin molecule may influence absorp-
tion. Binding of heparin to tissue proteins or 
inactivation by tissue enzymes may also be in-
volved, but this has not yet been documented. 
There is considerable evidence that, in some 
instances, "resistance" to the antithrombotic 
effects of heparin may be related to the altered 
physiology of the patient rather than to the drug 
itself. Patients with very extensive thrombotic 
processes, especially in conjunction with 
malignant neoplasm or certain septicemias or 
endotoxemias, and those with a vasculitis are 
very refractory to heparin therapy. Certain sub-
jects with recurrent venous thrombosis have 
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been reported to have more satisfactory 
therapeutic responses from antiplatelet agents 
than from prolonged heparin therapy. The rare 
patients with antithrombin III deficiency and re-
current thromboses do not have an adequate an-
ticoagulant response to heparin because the 
principal action of heparin is mediated by an 
acceleration of the complexing of antithrombin 
with thrombin and other serine proteases. The 
efficacy of low doses of subcutaneous heparin 
in the prevention of venous thromboembolism 
varies with the nature of the patient's primary 
problem, being of limited benefit in subjects 
with hip fracture or total hip replacement, 
presumably because the extensive trauma to tis-
sues accompanying these conditions brings 
about a coagulative abnormality or results in a 
degree of venous trauma which is less respon-
sive to the antithrombotic effects of low doses 
of heparin. Although the above explanation ap-
pears to explain the failure of heparin therapy in 
these conditions, it remains speculative and 
does not eliminate the possibility that an im-
proved and uniformly potent heparin prepara-
tion might be more effective in treatment. 
An equally important element in the variable 
effectiveness of heparin may be the result of 
clinical errors in the method of administration 
and in dose and procedures for monitoring ther-
apy. Recent pharmacokinetic studies have 
shown that after intravenous injection heparin is 
distributed in the plasma volume5 and has a 
mean anticoagulant half-life in the circulation of 
90 min. These findings would favor the calcu-
lation of dose on the basis of ideal body weight 
(as a reflection of plasma volume) and the ad-
ministration of drug either by continuous infu-
sion or very frequent intermittent intravenous 
injection. Although this approach is being in-
creasingly adopted, there is at present no uni-
form method of therapy. A recent randomized 
prospective trial has shown that patients receiv-
ing constant infusions of heparin had an approx-
imately 8-fold reduction in hemorrhagic com-
plications when compared with a group receiv-
ing intermittent intravenous injections; there 
were too few thrombotic complications to de-
termine differences. 14 The decreased frequency 
of bleeding is readily explainable since the ex-
cessive prolongation of clotting tests produced 
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by an intravenous bolus of heparin is avoided. 
An important ancillary finding of the above 
study was that, with the use of a predetermined 
level of anticoagulation as reflected by the acti-
vated partial thromboplastin time (APTT), the 
patients receiving constant infusion required 
about 25% less heparin than those receiving 
bolus injections. On the basis of this and an-
other similar prospective trial,6 continuous in-
fusion appears to lessen the risk of hemorrhage 
over that observed in patients receiving inter-
mittent intravenous injections at 4-hr intervals 
and also to lessen the dosage of drug. Hemor-
rhagic risk from intermittent injections might 
also be reduced if Estes'5 recommendation for 
injection at 11f2-hr intervals is followed, but this 
routine would place an excessive burden upon 
nursing staff. Subcutaneous injection of heparin 
at 8-or 12-hr intervals may be equally effective 
in reduction of frequency of bleeding complica-
tions, but such a prospective trial has not yet 
been conducted. None of these routes of admin-
istration has been shown to be superior as far as 
reduction of thrombotic sequelae in man is con-
cerned. 
A major issue in improvement of the effec-
tiveness of heparin therapy is whether periodic 
monitoring of the level of anticoagulation is of 
value. Ideally, if one knew the level of an-
ticoagulation which was associated with maxi-
mum antithrombotic effectiveness and mini-
mum risk of bleeding, there would be no ques-
tion; but these two criteria may be incompatible 
since optimal suppression of thrombosis may 
require the acceptance of an appreciable inci-
dence of bleeding. In addition, current mea-
sures of "anticoagulant" activity may not be 
the most suitable procedures to define anti-
thrombotic effect. 
Although monitoring patients receiving in-
termittent intravenous injections of heparin has 
not reduced risk of hemorrhage, 14 clotting tests 
have been performed during constant infusions 
or periodic subcutaneous injections of heparin 
in order to assure an adequate anticoagulant ef-
fect and prevent excessive prolongation of clot-
ting in the face of considerable interindividual 
variability in response. Basu and associates4 
have reported that the 5 patients who developed 
recurrent thromboembolism in a group of sub-
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jects receiving constant infusions of equivalent 
amounts of heparin for treatment of venous 
thromboembolism had significantly lesser pro-
longations of APTT than patients without recur-
rence. Although this observation supports the 
premise that anticoagulant and antithrombotic 
effect are correlated, conflicting opinions have 
been expressed concerning the adequacy of the 
APTT for monitoring heparin therapy. 
A principal objection to this test is that an 
appreciable proportion of hospitalized patients 
not receiving heparin have abnormal prolonga-
tions of the APTT. In addition, the standard 
procedure usually requires modification and 
careful calibration if it is used to determine 
blood levels of heparin; certain reagents (e. g. , 
ellagic acid) are unsuitable since they make the 
test relatively insensitive to varying concen-
trations of heparin. 
Many investigators have advocated other 
procedures, such as thrombin time, assay offac-
tor Xa inactivation, polybrene titration, or acti-
vated recalcification times, as being more accu-
rate or more sensitive to heparin effects. For the 
most part, Lee-White clotting times have been 
abandoned as too time consuming and inaccu-
rate. As Rosenberg13 has recently pointed out, 
however, all of these procedures are based upon 
the determination of the degree of "activation" 
by heparin of plasma antithrombin by measur-
ing in vitro its effect upon an added amount of a 
serine protease or its inhibitory effect upon 
serine proteases generated in plasma in vitro by 
kaolin addition (APTT). He questions whether 
these techniques reflect the effect of heparin-
activated antithrombin on serine proteases cir-
culating in vivo and proposes that a more satis-
factory monitoring technique might be based 
upon measurement in vivo of levels of the sev-
eral serine proteases (factors XII, XI, X, IX, ii). 
If such an approach could be developed and if it 
proves to be practical and economically feasi-
ble, it might provide a mechanism for "fine-
tuning" of the coagulation mechanism so that 
lesser amounts of heparin would be required. 
Some of the factors which have been dis-
cussed as possibly responsible for the variability 
in effectiveness of heparin may not be correct-
able. It seems quite likely, however, that in 
view of the recent demonstration of "active" 
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and "inactive" forms of heparin, the composi-
tion of this drug can be made more uniform. 
Greater knowledge concerning the physical and 
chemical structure of the molecule could lead to 
development of a chemical assay which is more 
accurate than current methods. Since individual 
patients will always differ in their coagulation 
profile, further clinical investigation of the 
therapeutic effectiveness of differing methods 
of administration and techniques for monitoring 
level of anticoagulation and antithrombotic 
efficacy may be productive in lessening hemor-
rhagic and thrombotic complications. Some of 
the variability in response to heparin in certain 
patients may be related to a concomitant 
deficiency of antithrombin; administration of 
exogenous antithrombin in conjunction with 
heparin might improve its antithrombotic effect. 
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